Paul Tudor Jones’s Quince Therapeutics QNCX Stock Holding History

Paul Tudor Jones’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.14M	Buy	+117,800	New	+$2.71M	﹤0.01%	1904

Other funds holding QNCX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paul Tudor Jones's QNCX Position: Q4 2021 in Review

Paul Tudor Jones sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 16 shares — an estimated $294K sold.

Paul Tudor Jones first reported a position in QNCX in Q3 2021 and held it in 1 quarter. The position peaked at $294K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

Paul Tudor Jones reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
Paul Tudor Jones sold 16 Quince Therapeutics shares in Q4 2021, an estimated $294K.
Paul Tudor Jones first reported a position in Quince Therapeutics in Q3 2021 and held it in 1 quarter.
Paul Tudor Jones's Quince Therapeutics position peaked at $294K in Q3 2021.
97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Tudor Investment Corp's 13F filing for Q4 2021, filed 14 Feb 2022.